Galanopoulos Andreas Neurologist

Education & Academic Qualifications

PhD in Neurosciences, grade “excellent” (2013)
M.Sc. in Neurosciences, grade “excellent” (2004)
Title of medical specialty of Neurology (2008)
Graduation of the Medical School of National and Kapodistrian University of Athens (1998)

Doctoral thesis

The role of the endogenous cannabinoid system in behavioural and neurobiological aspects of cognition. An experimental study in rats.

Fellowship in Societies, Membership in Journal Editorial Committees

Member of the European Academy of Neurology
Member of the International Parkinson and Movement Disorder Society
Member of the Hellenic Neurological Association
Member of the Athens Association of Alzheimer’s Disease and Related Disorders

Work Experience

Neurologist at the HYGEIA Hospital since 2012
Private neurological office in Pallini, Attiki, since 2008
Resident at the Neurology Department of the General Hospital of Piraeus “o Ag. Panteleimon”, 2004-2008
Resident at the 2nd Psychiatry Department of Psychiatric Hospital of Chania, Crete, 2002-2003
Participation in scientific activities of the Laboratory of Neurosciences and Behaviour, at Psychology Department of University of Crete, 2003-2004
Resident at the 2nd Internal Medicine Department of the General Hospital of Athens “Elpis”, 2002
Military service in the Hellenic Army as a doctor, 2000-2001
Rural medical service at the Hospital of Molai, Lakonia, 1998-2000

Education Experience:

Contribution in education of medical, biology, psychology undergraduate and postgraduate students

Clinical & Research Interest

Clinical Interest:

Memory deficits – Alzheimer’s Disease and other types of dementia
Multiple Sclerosis and other demyelinating disorders
Parkinson’s Disease and movement disorders
Headache, neuralgia and neuropathic pain
Diseases of the Spinal Cord and Peripheral Nerves (neuritis and neuropathies)

Research Interest:

Neurosciences-Brain neurotransmission
Neurobiological mechanisms involved in memory and learning
Cognition and Dementia
Parkinson’s Disease and other neurodegenerative disorders

Honors & Awards

Granted by “Latsis Foundation” during all years of undergraduate and postgraduate studies
More than 15 lectures in Congresses concerning Dementia and Parkinson’s Disease

Recent Publications

WIN55,212-2 impairs non-associative recognition and spatial memory in rats via CB1 receptor stimulation. Pharmacol Biochem Behav. 2014 Sep;124:58-66,Galanopoulos A, Polissidis A, Georgiadou G, Papadopoulou-Daifoti Z, Nomikos GG, Pitsikas N, Antoniou K
The effectiveness of memantine in a “behaviourally disturbed” AD population. Re-sults from a Greek observational, open-label, 6-month study. Journal of the Neuro-logical Sciences 333 (2013):e351, Galanopoulos A, Saltos L, Kerezoudi E, Parashos I
Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine. Behav Brain Res. 2014 Aug 15;270:261-9, Polissidis A, Chouliara O, Galanopoulos A, Naxakis G, Papahatjis D, Papadopoulou-Daifoti Z, Antoniou K
The cannabinoid CB1 receptor biphasically modulates motor activity and regulates dopamine and glutamate release region dependently. Int J Neuropsychopharma-col. 2013 Mar;16(2):393-403, Polissidis A, Galanopoulos A, Naxakis G, Papahatjis D, Papadopoulou-Daifoti Z, An-toniou K
Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dement Geriatr Cogn Disord. 2011;32(4):267-72, Forstl H, Stamouli SS, Janetzky W, Galanopoulos A, Karageorgiou C, Tzanakaki M
Δ(9)-THC and WIN55,212-2 affect brain tissue levels of excitatory amino acids in a phenotype-, compound-, dose-, and region-specific manner. Behav Brain Res. 2011 Oct 10;224(1):65-72, Galanopoulos A, Polissidis A, Papadopoulou-Daifoti Z, Nomikos GG, Antoniou K
Extensive hypertensive encephalopathy completely reversed after successful treatment. European Journal of Neurology 17 (2010, Suppl. 3), 72–350, Galanopoulos A, Xifaras M, Polissidis A, Papadopoulou-Daifoti Z
Ιndividual differences in the effects of cannabinoids on motor activity, dopaminer-gic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol. 2010 Oct;13(9):1175-91, Polissidis A, Chouliara O, Galanopoulos A, Rentesi G, Dosi M, Hyphantis T, Marselos M, Papadopoulou-Daifoti Z, Nomikos GG, Spyraki C, Tzavara ET, Antoniou K
Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure. Life Sci. 2009 Jul 31;85(5-6):248-54, Polissidis A, Chouliara O, Galanopoulos A, Marselos M, Papadopoulou-Daifoti Z, An-toniou K
Behavioral pharmacological properties of a novel cannabinoid 1′,1′-dithiolane del-ta8-THC analog, AMG-3. Behavioural Pharmacology. 2005 Sep; 16(5-6):499-510. An-toniou K, Galanopoulos A, Vlachou S, Kourouli T, Nahmias V, Thermos K, Panagis G, Daifoti Z, Marselos M, Papahatjis D, Spyraki C